News

Victoria Richon is a scientifically trained executive with leadership experience in biotechnology companies, global pharmaceutical companies and academia. Currently, Dr. Richon is the CEO at Entact Bio. Before joining Entact, Dr. Richon was the President and CEO of Ribon Therapeutics, a clinical stage biotechnology company focused on the discovery and development of first-in-class cancer and…

Eric is an investor at Mubadala Capital based in the San Francisco office. His training is in therapeutics discovery and preclinical development and early-stage business development and licensing. Previously, Eric was Vice President of Asset Acquisition at BridgeBio Pharma responsible for company creation and operations across multiple therapeutic areas. At BridgeBio he led the creation…

Eric is a Partner at DCVC Bio, a life science venture capital firm. Previously, he was a Partner at Novo Ventures where he helped establish and managed the firm’s public equities strategy focused on smidcap and late-stage private companies in biotech and medtech. Earlier in his career he was a Director at Apposite Capital after…

Marianne is a Partner at Apollo Health Ventures and responsible for Apollo’s investment and company building activities. Prior to joining the Apollo team, Marianne was a Principal with Wellington Partners, a pan-European Venture Capital firm investing in early- and growth-stage Life Science companies. In this role she led Wellington’s investments in Confo Therapeutics and Imcheck…

Alexandra joined Polaris Partners in 2019 and serves as a partner in the New York office. She is primarily focused on early stage biotech and healthcare investments. She currently serves on the Board of Directors of BeMeHealth, Podimetrics, SunBird Bio, and Trex Bio, and as a Board Observer to Engine Bio. Prior to joining Polaris,…

Brad Robling is the Vice President of Corporate Business Development / Lilly New Ventures at Eli Lilly and Company. As such, he is focused on managing Eli Lilly’s venture capital investments globally. Prior to joining the Eli Lilly venture team, he held positions in business development and investor relations.  Prior to joining Lilly, he held…

Dr. Morrison received his B.S. in biology from Georgetown University, his M.D. from the University of Connecticut Medical School, completed residency training in Internal Medicine at the Massachusetts General Hospital, and completed a fellowship in Medical Oncology at Dana-Farber Cancer Institute. He did postdocs with Philip Leder at Harvard Medical School, and Lee Nadler at…

Dr. Alon Lazarus joined Arkin Holdings’ pharma division in 2013. He serves on the board of several of Arkin’s pharmaceutical companies, including Keros Therapeutics, and Lutris Pharma. Prior to joining Arkin, Dr. Lazarus worked for the healthcare business development department of Yissum, the R&D arm of the Hebrew University of Jerusalem. Dr. Lazarus holds a…